Peptides Similar to PT-141
Compare PT-141 with related peptides and alternatives
📌TL;DR
- •4 similar peptides identified
- •Melanotan-2: PT-141 is derived directly from Melanotan-2. Both are cyclic melanocortin receptor agonists with the same core His-D-Phe-Arg-Trp pharmacophore and both produce sexual arousal effects via MC4R.
- •Melanotan-1: Both are synthetic melanocortin receptor agonists. Melanotan-1 (afamelanotide) is also FDA-approved but for a different indication (erythropoietic protoporphyria).
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| PT-141 (current) | - | - |
| Melanotan-2 | PT-141 is derived directly from Melanotan-2. Both are cyclic melanocortin receptor agonists with the same core His-D-Phe-Arg-Trp pharmacophore and both produce sexual arousal effects via MC4R. | Melanotan-2 has stronger MC1R activity causing skin tanning. PT-141 has a free carboxyl C-terminus vs amide in MT-2. MT-2 is not FDA-approved while PT-141 is approved as Vyleesi. |
| Melanotan-1 | Both are synthetic melanocortin receptor agonists. Melanotan-1 (afamelanotide) is also FDA-approved but for a different indication (erythropoietic protoporphyria). | Melanotan-1 is a linear 13-amino acid analog of alpha-MSH with strong MC1R selectivity for melanogenesis. PT-141 is a cyclic 7-amino acid peptide optimized for MC4R and sexual function. They target different receptor subtypes and different clinical indications. |
| Oxytocin | Both are peptides studied for effects on sexual function and reproductive behavior. Both act through central nervous system pathways. | Oxytocin is a 9-amino acid endogenous neuropeptide acting on oxytocin receptors. PT-141 is a synthetic melanocortin agonist. They act through completely different receptor systems and neural pathways. |
| Gonadorelin | Both are peptides in the reproductive category. Both affect hypothalamic-pituitary-gonadal axis signaling, though through different mechanisms. | Gonadorelin is a GnRH analog that directly stimulates gonadotropin release. PT-141 activates melanocortin receptors to enhance sexual desire. They have fundamentally different targets and indications. |
Melanotan-2PT-141 is derived directly from Melanotan-2. Both are cyclic melanocortin receptor agonists with the same core His-D-Phe-Arg-Trp pharmacophore and both produce sexual arousal effects via MC4R.
Differences
Melanotan-2 has stronger MC1R activity causing skin tanning. PT-141 has a free carboxyl C-terminus vs amide in MT-2. MT-2 is not FDA-approved while PT-141 is approved as Vyleesi.
Advantages
PT-141 has FDA approval, full clinical trial data, and defined dosing. MT-2 is less expensive and produces skin tanning as an additional effect.
Disadvantages
PT-141 is more expensive as the branded product. MT-2 has higher melanogenesis risk (nevi changes, melanoma concern) but broader research applications.
Melanotan-1Both are synthetic melanocortin receptor agonists. Melanotan-1 (afamelanotide) is also FDA-approved but for a different indication (erythropoietic protoporphyria).
Differences
Melanotan-1 is a linear 13-amino acid analog of alpha-MSH with strong MC1R selectivity for melanogenesis. PT-141 is a cyclic 7-amino acid peptide optimized for MC4R and sexual function. They target different receptor subtypes and different clinical indications.
Advantages
PT-141 targets sexual dysfunction. Melanotan-1 targets skin photoprotection. Both have FDA-approved indications, which is rare for research peptides.
Disadvantages
They are not interchangeable. PT-141 causes nausea in 40% of users. Melanotan-1 does not significantly affect sexual function.
OxytocinBoth are peptides studied for effects on sexual function and reproductive behavior. Both act through central nervous system pathways.
Differences
Oxytocin is a 9-amino acid endogenous neuropeptide acting on oxytocin receptors. PT-141 is a synthetic melanocortin agonist. They act through completely different receptor systems and neural pathways.
Advantages
PT-141 has FDA approval for sexual dysfunction. Oxytocin has broader endogenous roles and more extensive research across social, reproductive, and cardiovascular areas.
Disadvantages
Different mechanisms make direct comparison inappropriate. PT-141 specifically targets desire while oxytocin's sexual effects are secondary to its bonding and social role.
GonadorelinBoth are peptides in the reproductive category. Both affect hypothalamic-pituitary-gonadal axis signaling, though through different mechanisms.
Differences
Gonadorelin is a GnRH analog that directly stimulates gonadotropin release. PT-141 activates melanocortin receptors to enhance sexual desire. They have fundamentally different targets and indications.
Advantages
PT-141 directly addresses sexual desire. Gonadorelin addresses gonadal function and fertility. Both have established clinical applications.
Disadvantages
They are not alternatives to each other. They address different aspects of reproductive function.
Peptides Related to PT-141#
PT-141 (bremelanotide) is a melanocortin receptor agonist with FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its position as one of only two FDA-approved treatments for female sexual dysfunction (along with flibanserin) makes it uniquely situated in the peptide landscape. Understanding how PT-141 compares with related peptides and treatments provides important context for researchers and healthcare providers.
The most relevant comparisons involve other melanocortin system peptides (Melanotan-2, Melanotan-1) and other agents that affect sexual function through central or reproductive pathways.
PT-141 vs Melanotan-2#
The closest comparison to PT-141 is Melanotan-2 (MT-2), as PT-141 is a direct derivative of MT-2. The two peptides share the same cyclic core and pharmacophore but differ in a single structural feature with significant clinical implications.
Structural Relationship#
PT-141 is derived from Melanotan-2 and differs only at the C-terminus:
- Melanotan-2: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 (amidated)
- PT-141: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH (free carboxyl)
This single modification (amide vs carboxyl at the C-terminus) alters the receptor binding profile, reducing MC1R-mediated melanogenesis while preserving MC4R-mediated sexual function effects.
Clinical Implications#
| Feature | PT-141 | Melanotan-2 |
|---|---|---|
| FDA status | Approved (Vyleesi) | Not approved |
| Primary indication | HSDD in premenopausal women | None (research only) |
| Skin tanning effect | Minimal | Significant |
| Sexual function effect | Primary effect | Secondary effect |
| MC1R activity | Lower | Higher |
| MC4R activity | Preserved | Present |
| Nausea rate | ~40% (clinical trial data) | Unknown (no trial data) |
| Dosing data | 1.75 mg SC established | No established human dose |
| Safety database | Comprehensive (Phase 3 + post-marketing) | Limited |
| Cost | Prescription drug pricing | Research chemical pricing |
The Tanning vs Sexual Function Trade-Off#
Melanotan-2's strong MC1R activity produces skin tanning, which is the primary reason many individuals use it. However, this MC1R activity also carries concerns about nevi changes, potential melanoma risk, and uncontrolled hyperpigmentation. PT-141's reduced MC1R activity minimizes these risks while preserving the desired sexual function effects.
For researchers studying melanocortin pharmacology, MT-2 provides a broader receptor activation profile, while PT-141 is more suitable for studying MC4R-mediated sexual function specifically.
PT-141 vs Melanotan-1 (Afamelanotide)#
Melanotan-1 (afamelanotide, marketed as Scenesse) is a linear 13-amino acid synthetic analog of alpha-MSH. It was FDA-approved in 2019 (the same year as PT-141) for the treatment of erythropoietic protoporphyria (EPP), a rare genetic condition causing extreme light sensitivity.
Receptor Selectivity Comparison#
The key difference between PT-141 and Melanotan-1 is receptor selectivity:
| Feature | PT-141 | Melanotan-1 |
|---|---|---|
| Structure | Cyclic heptapeptide | Linear tridecapeptide |
| Amino acids | 7 | 13 |
| Primary receptor | MC4R | MC1R |
| MC1R activity | Moderate | High |
| MC4R activity | High | Low-moderate |
| FDA indication | HSDD | Erythropoietic protoporphyria |
| Sexual function effect | Primary | Minimal |
| Tanning effect | Minimal | Significant (therapeutic) |
| Administration | SC auto-injector, as needed | SC implant, monthly |
These two FDA-approved melanocortin agonists demonstrate how structural modifications can shift the therapeutic application of melanocortin peptides from one physiological system (pigmentation with Melanotan-1) to another (sexual function with PT-141).
PT-141 vs Flibanserin#
While flibanserin (Addyi) is not a peptide, it is the only other FDA-approved treatment for HSDD and represents the most clinically relevant comparison for PT-141.
Mechanism Comparison#
| Feature | PT-141 (Vyleesi) | Flibanserin (Addyi) |
|---|---|---|
| Drug class | Melanocortin receptor agonist | 5-HT1A agonist / 5-HT2A antagonist |
| Mechanism | MC4R activation, dopamine release | Serotonin-dopamine balance |
| Route | Subcutaneous injection | Oral tablet |
| Dosing | As needed (before sexual activity) | Daily (100 mg at bedtime) |
| Onset | ~45 minutes before activity | Weeks of daily dosing |
| FDA approval | 2019 | 2015 |
| Main side effect | Nausea (40%) | Somnolence, dizziness |
| Alcohol restriction | None | Contraindicated with alcohol |
| Indication | Premenopausal HSDD | Premenopausal HSDD |
Practical Considerations#
PT-141's on-demand dosing offers practical advantages for patients who do not want to take a daily medication. However, the subcutaneous injection requirement and the 40% nausea rate are significant barriers. Flibanserin's oral administration is more convenient but requires daily dosing and carries a contraindication with alcohol that limits social flexibility.
No head-to-head clinical trial has compared PT-141 with flibanserin, making direct efficacy comparison impossible from the available evidence.
PT-141 vs Oxytocin#
Oxytocin is a 9-amino acid endogenous neuropeptide produced in the hypothalamus with well-established roles in labor, lactation, bonding, and social behavior. While oxytocin is sometimes discussed in the context of sexual function, its mechanism and therapeutic applications are fundamentally different from PT-141.
Different Aspects of Sexual Function#
| Aspect | PT-141 | Oxytocin |
|---|---|---|
| Target system | Melanocortin/dopamine | Oxytocin receptor |
| Primary sexual effect | Desire and motivation | Bonding and orgasm |
| Phase of sexual response | Desire (appetitive) | Resolution (consummatory) |
| FDA indication | HSDD | Labor induction (Pitocin) |
| Research stage for sex | FDA-approved | Investigational |
PT-141 addresses the desire and motivational aspects of sexual function, while oxytocin's effects on sexual function are primarily related to pair bonding, trust, and the orgasmic response. They target different phases of the sexual response cycle and are not direct alternatives.
PT-141 vs Gonadorelin#
Gonadorelin (gonadotropin-releasing hormone, GnRH) is the endogenous hypothalamic hormone that controls the release of LH and FSH from the anterior pituitary. While both PT-141 and gonadorelin are in the reproductive category, they address completely different aspects of reproductive function.
Functional Comparison#
| Feature | PT-141 | Gonadorelin |
|---|---|---|
| Type | Synthetic melanocortin agonist | Endogenous GnRH analog |
| Target | MC4R in hypothalamus | GnRH receptors in pituitary |
| Function | Sexual desire enhancement | Gonadotropin release |
| Clinical use | HSDD | Fertility, diagnostic testing |
| Effect on hormones | Small LH/FSH/T increases | Direct LH/FSH stimulation |
These peptides are not alternatives to each other and address fundamentally different aspects of reproductive biology.
Comparison Summary Table#
| Feature | PT-141 | Melanotan-2 | Melanotan-1 | Oxytocin | Gonadorelin |
|---|---|---|---|---|---|
| MW | 1025 Da | 1024 Da | 1647 Da | 1007 Da | 1182 Da |
| Amino acids | 7 | 7 | 13 | 9 | 10 |
| Structure | Cyclic | Cyclic | Linear | Cyclic (disulfide) | Linear |
| Primary receptor | MC4R | MC1R/MC4R | MC1R | OTR | GnRH-R |
| FDA-approved | Yes (HSDD) | No | Yes (EPP) | Yes (labor) | Yes (fertility) |
| Sexual function | Primary effect | Secondary effect | Minimal | Bonding/orgasm | Indirect |
| Half-life | 2.7 hr | ~1-2 hr | ~0.5 hr | ~3-5 min | ~2-4 min |
| Route | SC injection | SC injection | SC implant | IV/intranasal | IV/SC |
Evidence Gaps#
- No head-to-head comparison trials between PT-141 and flibanserin
- Limited comparison data between PT-141 and Melanotan-2 at equivalent doses
- Whether combination of PT-141 with oxytocin or other agents enhances sexual function is unstudied
- Comparative receptor selectivity profiles need more detailed in vivo characterization
- Whether sequential or combination use with other agents improves outcomes is unexplored
Related Reading#
Frequently Asked Questions About PT-141
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer